References
- Picchioni MM , MurrayRM. Schizophrenia. BMJ335(7610) , 91–95 (2007).
- Buckley PF , MillerBJ, LehrerDS, CastleDJ. Psychiatric comorbidities and schizophrenia. Schizophr. Bull.35(2) , 383–402 (2009).
- Lin E , TsaiSJ. Gene–gene interactions in a context of individual variability in antipsychotic drug pharmacogenomics. Curr. Pharmacogenomics Person. Med.9(4) , 323–331 (2011).
- van Os J , KapurS. Schizophrenia. Lancet374(9690) , 635–645 (2009).
- Lane HY , LeeCC, LiuYC, ChangWH. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics6(2) , 139–149 (2005).
- Cacabelos R , HashimotoR, TakedaM. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin. Neurosci.65(1) , 3–19 (2011).
- Lin E , TsaiSJ. Novel diagnostics R&D for public health and personalized medicine in Taiwan: current state, challenges and opportunities. Curr. Pharmacogenomics Person. Med.10(3) , 239–246 (2012).
- Lin E . Novel drug therapies and diagnostics for personalized medicine and nanomedicine in genome science, nanoscience, and molecular engineering. Pharmaceutical Regulatory Affairs: Open Access1 , e116 (2012).
- Bhathena A , WangY, KraftJB et al. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. Transl. Psychiatry 3 , e245 (2013).
References
- Purdon SE , MallaA, LabelleA, LitW. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci.26 , 137–149 (2001).
- Kondo MA , TajindaK, ColantuoniC et al. Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control. Transl. Psychiatry 3 , e243 (2013).
- Abbas T , DuttaA. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer9 , 400–414 (2009).